Keyphrases
Alemtuzumab
100%
Anti-CD52 Antibody
16%
Antithymocyte Globulin
16%
Campath-1H
100%
Clinical High Risk
16%
Drug Maintenance
16%
Graft Survival
16%
High Risk
33%
Humanized
16%
Immunological Risk
100%
Immunosuppression
16%
Induction Protocol
16%
Infection Rate
16%
Maintenance Immunosuppression
16%
Maintenance Therapy
16%
Minimal Maintenance
16%
Monotherapy
100%
Mycophenolate
16%
Nonfunctioning
16%
Panel-reactive Antibody
16%
Primary Graft
16%
Randomized Controlled Trial
16%
Rejection Episodes
16%
Renal Transplant Recipients
33%
Renal Transplantation
100%
Reperfusion
16%
Tacrolimus
100%
Thymoglobulin
66%
Tolerogenic
33%
Immunology and Microbiology
Alemtuzumab
100%
Anti-Thymocyte Globulin
71%
Immunosuppression
28%
Infection Rate
14%
Kidney Transplantation
100%
Mycophenolic Acid
14%
Panel Reactive Antibody
14%
Reperfusion
14%
Tacrolimus
100%
Transplant Procedure
42%